Shona S. Pendse , David M. Briscoe , Markus H. Frank
{"title":"P-glycoprotein and alloimmune T-cell activation","authors":"Shona S. Pendse , David M. Briscoe , Markus H. Frank","doi":"10.1016/S1529-1049(03)00007-2","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in </span>cellular immunity<span> is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell<span> differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic </span></span></span>allograft<span> rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection<span>, the major causes of allograft dysfunction and ultimate graft loss.</span></span></p></div>","PeriodicalId":89340,"journal":{"name":"Clinical and applied immunology reviews","volume":"4 1","pages":"Pages 3-14"},"PeriodicalIF":0.0000,"publicationDate":"2003-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1529-1049(03)00007-2","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and applied immunology reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1529104903000072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic allograft rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection, the major causes of allograft dysfunction and ultimate graft loss.
p -糖蛋白(P-gp)是人类多药耐药(MDR1)基因产物和癌症多药耐药相关的三磷酸腺苷(ATP)结合盒(ABC)转运蛋白,在外周血单核细胞上有生理性表达,但其在细胞免疫中的作用才刚刚开始被阐明。P-gp在几种t细胞和抗原提呈细胞衍生的细胞因子分泌中的作用已被描述,并且该分子在淋巴细胞存活和抗原提呈细胞分化中的其他功能已被确定。综上所述,这些发现提供了令人信服的证据,证明P-gp在初级免疫反应的启动中具有几种不同的功能,并且该分子在功能性同种免疫反应中的关键作用现已确定。在这里,我们将回顾目前对P-gp通过t细胞和抗原呈递细胞依赖机制在同种免疫t细胞活化中的功能的理解,这与临床移植领域有关,P-gp已被发现是急性和慢性同种异体移植排斥反应的标志。事实上,目前的体外研究结果提出了P-gp可能代表急性和慢性同种异体移植排斥反应的新治疗靶点的可能性,同种异体移植功能障碍和最终移植损失的主要原因。